GBIO - Generation Bio Co.
After hours:
| Previous Close | 3.7800 |
| Open | 3.7800 |
| Bid | 3.6400 x 800 |
| Ask | 3.6700 x 800 |
| Day's Range | 3.5000 - 3.8725 |
| 52 Week Range | 3.4000 - 8.7150 |
| Volume | |
| Avg. Volume | 444,776 |
| Market Cap | 229.862M |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1300 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.33 |
GlobeNewswireGeneration Bio to Present at the 2023 Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2023 Jefferies Healthcare Conference Wednesday, June 7, 2023 at 1:30 p.m. EST in New York. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generat
ZacksGeneration Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -35.90% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results
Company entered into strategic collaboration with Moderna to use Generation Bio’s proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAM
- GlobeNewswire
Generation Bio to Present at the JMP Securities Life Sciences Conference
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023 at 1:00 p.m. EST in New York. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay wi
- GlobeNewswire
Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare on Tuesday, April 18th at 3:00 p.m. EST. A live webcast of the panel will be available on the investor section of the company’s website at investors.
Simply Wall St.Here's Why We're Not At All Concerned With Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- GlobeNewswire
Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. “We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic m
ZacksModerna (MRNA) Inks Genetic Medicines Deal With Generation Bio
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
- Reuters
UPDATE 2-Moderna signs licensing deal with Generation Bio in push beyond COVID
Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio.
- GlobeNewswire
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Collaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio’s ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program Moderna will fund all research and develop
- GlobeNewswire
Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in the Novel LNPs Targeting Diverse Tissues panel at the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines, which will take place virtually on Tuesday, March 28th at 10:00 a.m. ET. About Generation BioGeneration Bio is innova
- GlobeNewswire
Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 43rd Annual Cowen Healthcare Conference on Monday, March 6th at 10:30 a.m. EST in Boston, MA. A live webcast of the panel will be available on the investor section of the
- Simply Wall St.
Bullish insiders bet US$536k on Generation Bio Co. (NASDAQ:GBIO)
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- GlobeNewswire
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of $279.1M provides expected runway into 2025 CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2023 and reported fourth quarter and full year 2022 financial results. “Generation Bio is aiming to be the new
- GlobeNewswire
Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10th at 4:30 p.m. PST in San Francisco, CA. A live webcast of the company presentation will be available on the investor section of the company website at investors.generationbio.com. About Generation Bio
ZacksCan Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksWall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet
The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Cash balance of $301.2M expected to fund operations into 2025CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results. “Generation Bio’s mission is to unlock the full promise of genetic medicine by developing novel durable, redosable and titratable DNA therapeutics,” said Geoff McDonough, M.D.,
- Simply Wall St.
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com.
- GlobeNewswire
Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president. “Phillip has been instrumental in building a holistic strate
- Simply Wall St.
A number of insiders bought Generation Bio Co. (NASDAQ:GBIO) stock last year, which is great news for shareholders
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
ZacksGeneration Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireGeneration Bio Reports Business Highlights and Second Quarter 2022 Financial Results
Cash balance of $312.2M expected to fund operations into 2025CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progre
- GlobeNewswire
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be avai
